As was known, epirubicin, predominantly metabolized by the glucuronosyltransferase, has been clinically applied for breast cancer treatment (38); moreover, aromatase inhibitor treatment mainly functions for breast cancer by decreasing estrogen production (39). This evidence concerns the gene CYP19A1 and breast carcinoma.